“Introducing ‘HEDGE’: Sequential Intravesical Gemcitabine-Based Thermochemotherapy (HIVEC) Plus Docetaxel As a Potential Novel Bladder-Sparing Strategy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer”. Archivio Italiano di Urologia e Andrologia 98, no. 3 (September 9, 2026). Accessed October 3, 2026. https://www.pagepressjournals.org/aiua/article/view/15738.